C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen

Milestone Results in $8 Million Payment to C4 Therapeutics

WATERTOWN, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced it has successfully delivered a second development candidate to Biogen and earned an $8 million milestone payment. This marks the final development candidate under this strategic collaboration.

Read more at globenewswire.com